Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92150ArticlesСтатьиResearch ArticleEvropeyskie rekomendatsii po diagnostike i lecheniyu khronicheskoy serdechnoy nedostatochnosti 2005 g.: chto novogo v voprosakh farmakoterapii?Европейские рекомендации по диагностике и лечению хронической сердечной недостаточности 2005 г.: что нового в вопросах фармакотерапии?LopatinYu. MЛопатинЮ. МВолгоградский государственный медицинский университетВолгоградский областной кардиологический центр1505200685VOL 8, NO5 (2006)ТОМ 8, №5 (2006)11011328122021Copyright ©; 2006, Consilium MedicumCopyright ©; 2006, ООО "Консилиум Медикум"2006Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/92150

В июне 2005 г. эксперты Европейского общества кардиологов представили новые рекомендации по диагностике и лечению хронической сердечной недостаточности (ХСН), которые были опубликованы в виде двух отдельных документов – сокращенной и полной версии.Европейские рекомендации по диагностике и лечению ХСН 2005 г. аккумулировали последние достижения доказательной медицины в области СН. Они не только уточняют позиции лекарственных средств, применение которых обеспечивает достоверное снижение смертности и улучшение качества жизни, но и расширяют возможности практикующих врачей по выбору препаратов, рекомендованных для лечения этой патологии.

хроническая сердечная недостаточностьдоказательная медицинарекомендацииGuidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115–40.Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005): The Task Force for the Diagnosis and Treatment of CHF of the European Society of Cardiology. Eur Heart J 2005; doi: 10.1093/eurheartj/ehi205, p. 1–45.Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital administration in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–25.Pitt B et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348: 1309–21.Dickstein K et al. Effects of losartan and captopril on mortality and morbidity in high - risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60.Pfeffer M.A et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.Pfeffer M.A et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.Remme W.J, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527–60.Murray M.D et al. Open - label randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111: 513–20.Pitt B et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–17.Pitt B et al. on behalf of ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.Pitt B et al. on behalf of ELITE II Study Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.Conh J.N, Tognoni G. A randomized trial of the angiotensin - receptor blocker valsartan in CHF. N Engl J Med 2001; 345: 1667–75.Yusuf S et al. Effects of candesartan in patients with CHF and preserved left - ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.Mc Murray J.J et al. Effects of candesartan in patients with CHF and reduced left - ventricular systolic function taking angiotensin - converting - enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 676–771.Granger C.B et al. Effects of candesartan in patients with CHF and reduced left - ventricular systolic function intolerant to angiotensin - converting - enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.Rathore S.S et al. Sex - based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403–11.Rathore S.S et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871–8.